Abstract
B cell-specific Moloney murine leukemia virus integration site 1 (Bmi1) was identified as a biomarker of cancer stem cells, and over-expression of Bmi1 might enhance tumor aggressive clinical behavior in gastric cancer (GC). Our aim of this meta-analysis is to investigate the prognostic role and clinicopathological differences of Bmi1 in GC patients. A total of 6 studies up to September 2014 were included in our study. Our results showed that there were no relationships between Bmi1 expression and the gender (pooled OR=0.87, 95%CI=0.66-1.14, P=0.319, fixed effect), age (pooled OR=1.22, 95%CI=0.95-1.59, P=0.126, fixed effect) and differentiation (pooled OR=1.15, 95%CI=0.71-1.86, P=0.582, random effect) in GC patients. But high Bmi1 expression was significantly correlated with the clinical stage (pooled OR=3.04, 95%CI=1.31-7.07, P=0.010, random effect), tumor size (pooled OR=2.01, 95%CI=1.14-3.55, P=0.016, random effect), T classification (pooled OR=2.79, 95%CI=1.94-4.03, P<0.001, fixed effect), lymph node metastasis (pooled OR=2.24, 95%CI=1.47-3.39, P<0.001, random effect) and distant metastasis (pooled OR=5.05, 95%CI=1.29-19.70, P=0.020, random effect), and led to a poor overall survival (OS) in GC patients (RR=3.38, 95%CI=2.43-4.69, P<0.001, fixed effect). These findings suggested that Bmi1 might serve as a novel and effective prognostic biomarker in GC, and could be a promising emerging molecular target in GC therapy.
Keywords: Bmi1, gastric cancer, meta-analysis, prognosis.
Anti-Cancer Agents in Medicinal Chemistry
Title:Prognostic Value and Clinicopathological Differences of Bmi1 in Gastric Cancer: A Meta-analysis
Volume: 16 Issue: 4
Author(s): Bin Yuan, Hong Zhao, Xiaofeng Xue, Jin Zhou, Xu Wang, Ye Han, Lifeng Zhang, Xiaobo Guo and Qiaoming Zhi
Affiliation:
Keywords: Bmi1, gastric cancer, meta-analysis, prognosis.
Abstract: B cell-specific Moloney murine leukemia virus integration site 1 (Bmi1) was identified as a biomarker of cancer stem cells, and over-expression of Bmi1 might enhance tumor aggressive clinical behavior in gastric cancer (GC). Our aim of this meta-analysis is to investigate the prognostic role and clinicopathological differences of Bmi1 in GC patients. A total of 6 studies up to September 2014 were included in our study. Our results showed that there were no relationships between Bmi1 expression and the gender (pooled OR=0.87, 95%CI=0.66-1.14, P=0.319, fixed effect), age (pooled OR=1.22, 95%CI=0.95-1.59, P=0.126, fixed effect) and differentiation (pooled OR=1.15, 95%CI=0.71-1.86, P=0.582, random effect) in GC patients. But high Bmi1 expression was significantly correlated with the clinical stage (pooled OR=3.04, 95%CI=1.31-7.07, P=0.010, random effect), tumor size (pooled OR=2.01, 95%CI=1.14-3.55, P=0.016, random effect), T classification (pooled OR=2.79, 95%CI=1.94-4.03, P<0.001, fixed effect), lymph node metastasis (pooled OR=2.24, 95%CI=1.47-3.39, P<0.001, random effect) and distant metastasis (pooled OR=5.05, 95%CI=1.29-19.70, P=0.020, random effect), and led to a poor overall survival (OS) in GC patients (RR=3.38, 95%CI=2.43-4.69, P<0.001, fixed effect). These findings suggested that Bmi1 might serve as a novel and effective prognostic biomarker in GC, and could be a promising emerging molecular target in GC therapy.
Export Options
About this article
Cite this article as:
Yuan Bin, Zhao Hong, Xue Xiaofeng, Zhou Jin, Wang Xu, Han Ye, Zhang Lifeng, Guo Xiaobo and Zhi Qiaoming, Prognostic Value and Clinicopathological Differences of Bmi1 in Gastric Cancer: A Meta-analysis, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (4) . https://dx.doi.org/10.2174/1871520615666150507120801
DOI https://dx.doi.org/10.2174/1871520615666150507120801 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Aspects of FKBP51 that Enable Melanoma Dissemination
Current Molecular Pharmacology Efficacy of Yun Zhi (Coriolus versicolor) on Survival in Cancer Patients: Systematic Review and Meta-Analysis
Recent Patents on Inflammation & Allergy Drug Discovery Particulate Systems as Adjuvants and Carriers for Peptide and Protein Antigens
Current Drug Delivery Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents
Current Cancer Drug Targets OSI-027 Alleviates Oxaliplatin Chemoresistance in Gastric Cancer Cells by Suppressing P-gp Induction
Current Molecular Medicine Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Targeting CD4 to Disrupt Signaling Through Membrane Rafts: Towards a Raft-Based Therapeutics
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Taste Sensing in the Colon
Current Pharmaceutical Design Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression
Current Vascular Pharmacology Hecogenin Acetate Inhibits Reactive Oxygen Species Production and Induces Cell Cycle Arrest and Senescence in the A549 Human Lung Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Difluorinated Curcumin: A Promising Curcumin Analogue with Improved Anti-Tumor Activity and Pharmacokinetic Profile
Current Pharmaceutical Design MUC1 is a Promising Therapeutic Target for Prostate Cancer Therapy
Current Cancer Drug Targets Circadian Cycle and Chronotherapeutics: Recent Trend for the Treatment of Various Biological Disorders
Recent Patents on Drug Delivery & Formulation Histone Deacetylase Inhibitors and Anticancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents New Trends in Dual 5-LOX / COX Inhibition
Current Medicinal Chemistry Drug Transporters and Multiple Drug Resistance in the Most Common Pediatric Solid Tumors
Current Drug Metabolism Targeting the Nucleotide Metabolism Proteins of the NUDIX Family and SAMHD1 in Cancer
Current Medicinal Chemistry Nutrigenomics, β-Cell Function and Type 2 Diabetes
Current Genomics